Hepatocellular carcinoma (HCC) mostly occurs in the background of liver fibrosis, and activated hepatic stellate cells (HSCs) exist in HCC tissues and adjacent tissues. HSC activation is involved ...

Hepatocellular carcinoma (HCC), one of the most common and lethal tumors worldwide, is usually not diagnosed until the disease is advanced, which results in ineffective intervention and unfavorable ...

Transarterial chemoembolization (TACE) improves survival in cirrhotic patients with hepatocellular carcinoma (HCC). The optimal schedule, best anticancer agent and best technique are still unclear.

AI decision support system non-homogenously influences clinical decisions in dynamic treatment regimen, as it depends on several factors including prior knowledge, preference, disease type ...

We aim to elucidate the nature, regulation and functional relevance of PD-L1 + host cells in hepatocellular carcinoma (HCC). Design A total of untreated 184 HCC patients was enrolled randomly. C57BL/6 ...

We provide the first extensive analysis of RNA editing in the human liver cancer transcriptome. HCC, distinct from most cancer types, is neither a hypo- nor a hyper-editing cancer; instead, HCC ...

Background: Hepatoblastoma (HBL) and hepatocellular carcinoma (HCC) are respectively the first and the second most common pediatric malignant liver tumors. The purpose of this study was to ...

Niraparib in patients with BRCA-mutated unresectable or recurrent biliary tract, pancreatic and other gastrointestinal cancers: An investigator-initiated phase 2 trial (NIR-B trial). This is an ASCO ...

A global comparative study on MDT practices in the management of hepatocellular carcinoma in high-income countries (HICs) and low- and middle-income countries (LMICs). This is an ASCO Meeting Abstract ...

Hepatocellular carcinoma (HCC) represents a significant global health burden as one of the most common malignancies in individuals with chronic liver disease or cirrhosis. This malignancy evolves ...

According to GlobalData, Phase I drugs for Metastatic Hepatocellular Carcinoma (HCC) have an 80% phase transition success rate (PTSR ... The company offers its products in the US; Europe; Asia-Pacific ...